NLS

Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.

In a nation that’s historically strong in tech, Finnish pharmaceutical development still struggles to capture the imagination of investors. The Finnish Drug Discovery Center sets out to help early-stage life science companies take their first steps towards investments and clinical development.

When Cancer Crosslinks took place in Oslo on January 22, it marked the meeting’s 18th anniversary. It’s “really coming of age,” jokes Jutta Heix, the Head of International Affairs at Oslo Cancer Cluster, which organizes the meeting.

As global tensions rise and the United States moves in a more unpredictable direction, Europe’s life science sector is under pressure to strengthen its competitiveness. According to Medicon Valley Alliance's (MVA) CEO, Anette Steenberg, the Nordics have a decisive role to play – but only if the region can act as one.

Through bioprinting pioneers and stem cell innovators, Nordic researchers are redefining how organs and tissues can be repaired and regenerated.

With SEK 390 million in fresh funding and a Phase II trial in endometriosis underway, Gesynta Pharma’s CFO Michaela Gertz is navigating the financial complexities of a VC-backed biotech with precision and purpose.